“Akt–the Mammalian Target of Rapamycin (mTOR) Pathway Inhibition Increases Cervical Cancer Cell Chemosensitivity to Active Form of Irinotecan (SN-38)”. International Journal of Integrated Health Sciences, vol. 1, no. 1, Sept. 2013, pp. 13-21, https://journal.fk.unpad.ac.id/index.php/ijihs/article/view/103.